Dysphagia, Esophageal
Conditions
Brief summary
Evaluation of swallowing function and hydration following consumption of ThickenUp® Gel Express in patients with dysphagia.
Detailed description
ThickenUp® Gel Express for Patients With Dysphagia (Hydra-01 Study): Effect on Swallowing Function as Assessed by a Videofluoroscopy (VFS) One Day Study With Bolus of Various Viscosities (Study Part 1) and Followed, in a Subset of Patients, by a United Kingdom Advisory Committee on Borderline Substances (UK ACBS) Acceptability 14 Days Study Combined With an Exploratory Hydration Assessment Study at a Prescribed Viscosity (Study Part 2).
Interventions
DIETARY_SUPPLEMENTThickenUp® Gel Express
Thickening gel
Sponsors
Société des Produits Nestlé (SPN)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
prospective, open-label
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key inclusion criteria (for study part 1 and part 2): 1. Aged ≥ 18 years; 2. Diagnosed with oropharyngeal dysphagia and with a documented impaired safety of swallow by V-VST and PAS \>1 during VFS; 3. History and/or current of swallowing difficulties; 4. Willing to adhere to the restrictions specified in the protocol; 5. Must be competent to understand the nature of the study and capable of giving written informed consent. In case patients are not capable of providing written informed consent (i.e. affected by dementia) a family/legal representative could provide the consent for the study. 6. Willing to report for the scheduled study visits and communicate to study personnel about adverse events and concomitant medication use. Key
Exclusion criteria
(for study part 1 and part 2): 1. Patients suffering from idiosyncratic phenomena or who are allergic to iodinated contrast media; 2. Major respiratory disease requiring oxygen or undergoing any type of surgery in the three months prior to the study; 3. Current diarrhea, vomiting or abdominal pain; 4. Alcohol or drug dependence (based on anamnesis only); 5. COVID-19 positive patients (with or without symptoms) at the time of enrolment; 6. Patients who, in the judgment of the investigator, are likely to be noncompliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development; 7. Having participated in a clinical study in the last 4 weeks and received compensation beyond a certain approved and predefined limit; 8. Having a clinical condition that is contraindicated with the study product; 9. Positive urine pregnancy test at screening for women of childbearing potential; 10. Allergy towards milk, mustard, egg, or celery. Additional inclusion criteria for study part 2 only: 1. Patient willing to participate in study part 2; 2. Patient/caregiver able to record daily GI symptoms, compliance and fluid intake; 3. Patient able to respond to acceptability questionnaire (organoleptic properties, texture, appearance). 4. Patient willing to only use study product as the sole thickening agent during the Part 2. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Penetration-Aspiration Score (PAS) | 1 day | Part 1 -Bolus penetration into the laryngeal vestibule (PAS Score): the maximum PAS score across the different boluses assessed during videofluoroscopic (VFS) recording. |
| The United Kingdom Advisory Committee on Borderline Substances (UK ACBS) | 14 days | Part 2 |
Countries
Spain
Outcome results
None listed